Active surveillance for favorable risk prostate cancer: Rationale, risks, and results

被引:20
作者
Klotz, Laurence [1 ]
机构
[1] Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Urol, Toronto, ON, Canada
关键词
prostate cancer surveillance; PSA kinetics; doubling time; watchful waiting;
D O I
10.1016/j.urolonc.2007.05.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Active surveillance for favorable risk prostate cancer has become increasingly popular in populations where prostate cancer screening is widespread, due to evidence that prostate cancer screening results in the detection of disease that is not clinically significant in many patients (i.e., untreated, would not pose a threat to health). This approach is supported by data demonstrating that patients who fall into the category of clinically insignificant disease can be identified with reasonable accuracy, and that patients who are initially classified as low risk who reclassify over time as higher risk and are then treated more aggressively are in most cases still cured. An active surveillance approach means (1) identifying patients who have a low likelihood of disease progression during their lifetime, based on clinical and pathologic features of the disease and patient age and comorbidity; (2) monitoring closely over time, (3) establishing reasonable criteria for intervention, which will both identify more aggressive disease in a timely fashion, and not result in excessive treatment, and (4) meeting the communication challenge to reduce the psychological burden of living with untreated cancer. The results of active surveillance, the criteria for patient selection, and the appropriate triggers for intervention are reviewed. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:505 / 509
页数:5
相关论文
共 17 条
[1]   Prostate cancer and the Will Rogers phenomenon [J].
Albertsen, PC ;
Hanley, JA ;
Barrows, GH ;
Penson, DF ;
Kowalczyk, PDH ;
Sanders, MM ;
Fine, J .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17) :1248-1253
[2]   20-year outcomes following conservative management of clinically localized prostate cancer [J].
Albertsen, PC ;
Hanley, JA ;
Fine, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (17) :2095-2101
[3]   Radical prostatectomy versus watchful waiting in early prostate cancer [J].
Bill-Axelson, A ;
Holmberg, L ;
Ruutu, M ;
Häggman, M ;
Andersson, SO ;
Bratell, S ;
Spångberg, A ;
Busch, C ;
Nordling, S ;
Garmo, H ;
Palmgren, J ;
Adami, HO ;
Norlén, BJ ;
Johansson, JE .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (19) :1977-1984
[4]   Feasibility study: Watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression [J].
Choo, R ;
Klotz, L ;
Danjoux, C ;
Morton, GC ;
DeBoer, G ;
Szumacher, E ;
Fleshner, N ;
Bunting, P ;
Hruby, G .
JOURNAL OF UROLOGY, 2002, 167 (04) :1664-1669
[5]   Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy [J].
D'Amico, AV ;
Chen, MH ;
Roehl, KA ;
Catalona, WJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (02) :125-135
[6]   Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1C disease [J].
Epstein, JI ;
Walsh, PC ;
Carter, HB .
JOURNAL OF UROLOGY, 2001, 166 (05) :1688-1691
[7]  
Etzioni R, 2002, J NATL CANCER I, V94, P981
[8]   Cancer statistics, 2004 [J].
Jemal, A ;
Tiwari, RC ;
Murray, T ;
Ghafoor, A ;
Samuels, A ;
Ward, E ;
Feuer, EJ ;
Thun, MJ .
CA-A CANCER JOURNAL FOR CLINICIANS, 2004, 54 (01) :8-29
[9]   Active surveillance for prostate cancer: For whom? [J].
Klotz, L .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (32) :8165-8169
[10]  
KLOTZ L, 2004, J UROLOGY, V175, P48